Application of in silico, in vitro and preclinical pharmacokinetic data for the effective and efficient prediction of human pharmacokinetics

Molecular Pharmaceutics

Volumn 10, Issue 4, 2013, Pages 1191-1206

  Grime, Kenneth H ^a   Barton, Patrick ^a   McGinnity, Dermot F ^a  

^a ASTRAZENECA R AND D   (Sweden)

Author keywords

Drug Discovery; Drug Metabolism and Pharmacokinetics; in silico; in vitro in vivo extrapolation

Indexed keywords

ARTICLE; COMPUTER MODEL; COMPUTER PREDICTION; COST EFFECTIVENESS ANALYSIS; DECISION MAKING; DRUG ABSORPTION; DRUG CLEARANCE; DRUG DESIGN; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INFORMATION PROCESSING; NONHUMAN; PHARMACOKINETICS; PRIORITY JOURNAL;

ABSORPTION; ALGORITHMS; ANIMALS; COMPUTER SIMULATION; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; HUMANS; METABOLIC CLEARANCE RATE; MODELS, THEORETICAL; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; TECHNOLOGY, PHARMACEUTICAL;

EID: 84875779756     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp300476z     Document Type: Article

References (128)

1. Prentis, R. A.; Lis, Y.; Walker, S. R. Pharmaceutical innovation by the seven UK-owned pharmaceutical companies (1964-1985) Br. J. Clin. Pharmacol. 1988, 25, 387-396
2. Schuster, D.; Laggner, C.; Langer, T. Why drugs fail - a study on side effects in new chemical entities Curr. Pharm. Des. 2005, 11, 3545-3559
3. Kubinyi, H. Drug research: myths, hype and reality Nat. Rev. Drug Discovery 2003, 2, 665-668
4. Sams-Dodd, F. Optimizing the discovery organization for innovation Drug Discovery Today 2005, 10, 1049-1056
5. Macarron, R. Critical review of the role of HTS in drug discovery Drug Discovery Today 2006, 11, 277-279
6. Riley, R. J.; Kenna, J. G. Cellular models for ADMET predictions and evaluation of drug-drug interactions Curr. Opin. Drug Discovery Dev. 2004, 7, 86-99
7. Riley, R. J.; Grime, K. Metabolic screening in vitro: metabolic stability, CYP inhibition and induction Drug Discovery Today 2004, 1, 365-372
8. Leeson, P. D.; Springthorpe, B. The influence of drug-like concepts on decision-making in medicinal chemistry Nat. Rev. Drug Discovery 2007, 6, 881-890
9. McGinnity, D. F.; Collington, J.; Austin, R. P.; Riley, R. J. Evaluation of human pharmacokinetics, therapeutic dose and exposure predictions using marketed oral drugs Curr. Drug Metab. 2007, 8, 463-479
10. Grime, K.; Riley, R. J. The Impact of In Vitro Binding on In Vitro-In Vivo Extrapolations, Projections of Metabolic Clearance and Clinical Drug-Drug Interactions Curr. Drug Metab. 2006, 7, 251-264
11. Riley, R. J.; Martin, I. J.; Cooper, A. E. The influence of DMPK as an integrated partner in modern drug discovery Curr. Drug Metab. 2002, 3, 527-550
12. van de Waterbeemd, H.; Gifford, E. ADMET in silico modelling: towards prediction paradise? Nat. Rev. Drug Discovery 2003, 2, 192-204
13. Lipinski, C. A. Drug-like properties and the causes of poor solubility and poor permeability J. Pharmacol. Toxicol. Methods 2000, 44, 235-249
14. Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings Adv. Drug Delivery Rev. 1997, 23, 3-25
15. Gabrielsson., J.; Dolgos, H.; Gillberg, P. G.; Bredberg, U.; Benthem, B.; Duker, G. Early integration of pharmacokinetic and dynamic reasoning is essential for optimal development of lead compounds: strategic considerations Drug Discovery Today 2009, 14, 358-372
16. Malik, N. N. Drug discovery: past, present and future Drug Discovery Today 2008, 13, 909-912
17. Petrillo, E. W. Lean thinking for drug discovery-better productivity for pharma Drug Discovery World 2007, Spring) 9-14
18. Schmid, E. F.; Smith, D. A. Keynote review: Is declining innovation in the pharmaceutical industry a myth? Drug Discovery Today 2005, 1, 1031-1039
19. Sinha, G. Pharma bankrolls academic institutes Nat. Biotechnol. 2012, 30, 474
20. Hughes, B. China spurs pharma innovation Nat. Rev. Drug Discovery 2008, 7, 631-632
21. Hellriegel, E. T.; Bjornsson, T. D.; Hauck, W. W. Interpatient variability in bioavailability is related to the extent of absorption: implications for bioavailability and bioequivalence studies Clin. Pharmacol. Ther. 1996, 60, 601-607
22. Rowland, M.; Tozer, T. N. Clinical Pharmacokinetics-Concepts and Applications, 3 rd ed.; Williams and Wilkins: 1989.
23. Komura, H.; Iwaki, M. In vitro and in vivo small intestinal metabolism of CYP3A and UGT substrates in preclinical animals species and humans: species differences Drug Metab. Rev. 2011, 43, 476-498
24. Galetin, A.; Gertz, M.; Houston, J. B. Contribution of intestinal cytochrome p450-mediated metabolism to drug-drug inhibition and induction interactions Drug Metab. Pharmacokinet. 2010, 25, 28-47
25. Thelen, K.; Dressman, J. B. Cytochrome P450-mediated metabolism in the human gut wall J. Pharm. Pharmacol. 2009, 61, 541-558
26. Paine, M. F.; Hart, H. L.; Ludington, S. S.; Haining, R. L.; Rettie, A. E.; Zeldin, D. C. The human intestinal cytochrome P450 "pie" Drug Metab. Dispos. 2006, 34, 880-886
27. Zhang, Q. Y.; Dunbar, D.; Ostrowska, A.; Zeisloft, S.; Yang, J.; Kaminsky, L. S. Characterization of human small intestinal cytochromes P-450 Drug Metab. Dispos. 1999, 27, 804-809
28. Prueksaritanont, T.; Gorham, L. M.; Hochman, J. H.; Tran, L. O.; Vyas, K. P. Comparative studies of drug-metabolizing enzymes in dog, monkey, and human small intestines, and in Caco-2 cells Drug Metab. Dispos. 1996, 24, 634-642
29. Yang, J.; Jamei, M.; Yeo, K. R.; Tucker, G. T.; Rostami-Hodjegan, A. Prediction of intestinal first-pass drug metabolism Curr. Drug Metab. 2007, 8, 676-684
30. Doherty, M. M.; Charman, W. N. The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism? Clin. Pharmacokinet. 2002, 41, 235-253
31. Paine, M. F.; Khalighi, M.; Fisher, J. M.; Shen, D. D.; Kunze, K. L.; Marsh, C. L.; Perkins, J. D.; Thummel, K. E. Characterization of inter- and intra-intestinal differences in human CYP3A-dependent metabolism J. Pharmacol. Exp. Ther. 1997, 283, 1552-1562
32. Galetin, A.; Houston, J. B. Intestinal and hepatic metabolic activity of five cytochrome P450 enzymes: impact on prediction of first-pass metabolism J. Pharmacol. Exp. Ther. 2006, 318, 1220-1229
33. Galetin, A. Intestinal first-pass metabolism: bridging the gap between in vitro and in vivo Curr. Drug Metab. 2007, 8, 643-644
34. Zhang, Y.; Benet, L. Z. The gut as a barrier to drug absorption: combined role of cytochrome P450 3A and P-glycoprotein Clin. Pharmacokinet. 2001, 40, 159-168
35. Galetin, A.; Gert, M.; Houston, J. B. Potential role of intestinal firstpass metabolism in the prediction of drug-drug interactions Expert Opin. Drug Metab. Toxicol. 2008, 4, 909-922
36. Lin, X.; Skolnik, S.; Chen, X.; Wang, J. Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model Drug Metab. Dispos. 2011, 39, 265-274
37. Murakami, T.; Takano, M. Intestinal efflux transporters and drug absorption Expert Opin. Drug Metab. Toxicol. 2008, 4, 923-939
38. Bolger, M. B.; Lukacova, V.; Woltosz, W. S. Simulations of the nonlinear dose dependence for substrates of influx and efflux transporters in the human intestine AAPS J. 2009, 11, 353-363
39. Guidance for Industry Drug Interaction Studies-Study Design, Data Analysis, Implications for Dosing and Labeling Recommendations, U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER). 2012.
40. Hidalgo, I. J.; Raub, T. J.; Borchardt, R. T. Characterization of the human colon carcinoma cell line (Caco-2) as a model system for intestinal epithelial permeability Gastroenterology 1989, 96, 736-749
41. Sun, D.; Lennernas, H.; Welage, L. S.; Barnett, J. L.; Landowski, C. P.; Foster, D.; Fleisher, D.; Lee, K. D.; Amidon, G. L. Comparison of human duodenum and Caco-2 gene expression profiles for 12,000 gene sequences tags and correlation with permeability of 26 drugs Pharmacol. Res. 2002, 19, 1400-1416
42. Jamei, M.; Marciniak, S.; Feng, K.; Barnett, A.; Tucker, G.; Rostami-Hodjegan, A. The Simcyp population-based ADME simulator Expert Opin. Drug Metab. Toxicol. 2009, 5, 211-223
43. Sinha, V. K.; Snoeys, J.; Osselaer, N. V.; Peer, A. V.; Mackie, C.; Heald, D. From preclinical to human - prediction of oral absorption and drug-drug interaction potential using physiologically based pharmacokinetic (PBPK) modeling approach in an industrial setting: a workflow by using case example Biopharm. Drug Dispos. 2012, 33, 111-121
44. DeSesso, J. M.; Jacobson, C. F. Anatomical and physiological parameters affecting gastrointestinal absorption in humans and rats Food Chem. Toxicol. 2001, 39, 209-228
45. Øie, S.; Tozer, T. N. Effect of altered plasma protein binding on apparent volume of distribution J. Pharm. Sci. 1979, 68, 1203-1205
46. Lombardo, F.; Waters, N. J.; Argikar, U. A.; Dennehy, M. K.; Zhan, J.; Gunduz, M.; Harriman, S. P.; Berellini, G.; Liric Rajlic, I.; Obach, R. S. Comprehensive Assessment of Human Pharmacokinetic Prediction Based on In Vivo Animal Pharmacokinetic Data, Part 1: Volume of Distribution at Steady State J. Clin. Pharmacol. 2012, 10.1177/0091270012440281
47. Berry, L. M.; Li, D.; Zhao, Z. Species differences in distribution and prediction of human V(ss) from preclinical data Drug Metab. Dispos. 2011, 39, 2103-2116
48. Smith, D. A.; Kerns, E. H. The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery Nat. Rev. Drug Discovery 2010, 9, 929-939
49. MacIntyre, A. C.; Cutler, D. J. The potential role of lysosomes in tissue distribution of weak bases Biopharm. Drug Dispos. 1988, 9, 513-526
50. Cooper, A. E.; Ferguson, D.; Grime, K. Optimisation of DMPK by the inhaled route: challenges and approaches Curr. Drug Metab. 2012, 13, 457-473
51. Berry, L. M.; Roberts, J.; Be, X.; Zhao, Z.; Lin, M. H. Prediction of V(ss) from in vitro tissue-binding studies Drug Metab. Dispos. 2010, 38, 115-121
52. Gleeson, M. P.; Waters, N. J.; Paine, S. W.; Davis, A. M. In silico human and rat Vss quantitative structure-activity relationship models J. Med. Chem. 2006, 49, 1953-1963
53. Berellini, G.; Springer, C.; Waters, N. J.; Lombardo, F. In silico prediction of volume of distribution in human using linear and nonlinear models on a 669 compound data set J. Med. Chem. 2009, 52, 4488-4495
54. Zou, P.; Zheng, N.; Yang, Y.; Yu, L. X.; Sun, D. Prediction of volume of distribution at steady state in humans: comparison of different approaches Expert Opin. Drug Metab. Toxicol. 2012, 8, 855-872
55. Jones, R. D.; Jones, H. M.; Rowland, M.; Gibson, C. R.; Yates, J. W.; Chien, J. Y.; Ring, B. J.; Adkison, K. K.; Ku, M. S.; He, H.; Vuppugalla, R.; Marathe, P.; Fischer, V.; Dutta, S.; Sinha, V. K.; Björnsson, T.; Lavé, T.; Poulin, P. PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 2: Comparative assessment of prediction methods of human volume of distribution J. Pharm. Sci. 2011, 100, 4074-4089
56. Lombardo, F.; Waters, N. J.; Argikar, U. A.; Dennehy, M. K.; Zhan, J.; Gunduz, M.; Harriman, S. P.; Berellini, G.; Liric Rajlic, I.; Obach, R. S. Comprehensive Assessment of Human Pharmacokinetic Prediction Based on In Vivo Animal Pharmacokinetic Data, Part 2: Clearance J. Clin. Pharmacol. 2012, 10.1177/0091270012440282
57. Mahmood, I. Theoretical versus empirical allometry: Facts behind theories and application to pharmacokinetics J. Pharm. Sci. 2010, 99, 2927-2933
58. Ward, K. W.; Smith, B. R. A comprehensive quantitative and qualitative evaluation of extrapolation of intravenous pharmacokinetic parameters from rat, dog, and monkey to humans. I. Clearance Drug Metab. Dispos. 2004, 32, 603-611
59. Campbell, D. B. Extrapolation from animals to man. The integration of pharmacokinetics and pharmacodynamics Ann. N.Y. Acad. Sci. 1996, 801, 116-135
60. Sohlenius-Sternbeck, A.-K.; Jones, C.; Ferguson, D.; Middleton, B. J.; Projean, D.; Floby, E.; Bylund, J.; Afzelius, L. Practical use of the regression offset approach for the prediction of in vivo intrinsic clearance from hepatocytes Xenobiotica 2012, 42, 841-853
61. Lavé, T.; Chapman, K.; Goldsmith, P.; Rowland, M. Human clearance prediction: shifting the paradigm Expert Opin. Drug Metab. Toxicol. 2009, 9, 1039-1048
62. Ito, K.; Houston, J. B. Prediction of human drug clearance from in vitro and preclinical data using physiologically based and empirical approaches Pharm. Res. 2005, 22, 103-112
63. Houston, J. B. Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance Biochem. Pharmacol. 1994, 47, 1469-1479
64. Obach, R. S. Predicting clearance in humans from in vitro data Curr. Top. Med. Chem. 2011, 11, 334-339
65. Soars, M,G.; McGinnity, D. F.; Grime, K.; Riley, R. J. The pivotal role of hepatocytes in drug discovery Chem.-Biol. Interact. 2007a, 168, 2-15
66. Shitara, Y.; Li, A. P.; Kato, Y.; Lu, C.; Ito, K.; Itoh, T.; Sugiyama, Y. Function of uptake transporters for taurocholate and estradiol 17beta-D-glucuronide in cryopreserved human hepatocytes Drug Metab. Pharmacokinet. 2003, 18, 33-41
67. Riley, R. J.; McGinnity, D. F.; Austin, R. P. A unified model for predicting human hepatic, metabolic clearance from in vitro intrinsic clearance data in hepatocytes and microsomes Drug Metab. Dispos. 2005, 33, 1304-1311
68. Rawden, H. C.; Carlile, D. J.; Tindall, A.; Hallifax, D.; Galetin, A.; Ito, K.; Houston, J. B. Microsomal prediction of in vivo clearance and associated interindividual variability of six benzodiazepines in humans Xenobiotica 2005, 35, 603-625
69. Naritomi, Y.; Terashita, S.; Kagayama, A.; Sugiyama, Y. Utility of hepatocytes in predicting drug metabolism: comparison of hepatic intrinsic clearance in rats and humans in vivo and in vitro Drug Metab. Dispos. 2003, 31, 580-588
70. Poulin, P.; Kenny, J. R.; Hop, C. E.; Haddad, S. In vitro-in vivo extrapolation of clearance: modeling hepatic metabolic clearance of highly bound drugs and comparative assessment with existing calculation methods J. Pharm. Sci. 2012, 101, 838-851
71. Hallifax, D.; Houston, J. B. Evaluation of Hepatic Clearance Prediction Using In Vitro Data: Emphasis on fraction Unbound in Plasma and Drug Ionisation Using a database of 107 Drugs J. Pharm. Sci. 2012, 101, 2645-2652
72. Obach, R. S.; Reed-Hagen, A. E. Measurement of Michaelis constants for cytochrome P450-mediated biotransformation reactions using a substrate depletion approach Drug Metab. Dispos. 2002, 30, 831-837
73. Soars, M. G.; Grime, K.; Sproston, J. L.; Webborn, P. J.; Riley, R. J. Use of hepatocytes to assess the contribution of hepatic uptake to clearance in vivo Drug Metab. Dispos. 2007b, 36, 859-865
74. Austin, R. P.; Barton, P.; Cockfroft, S. L.; Wenlock, M. P.; Riley, R. J. The influence of nonspecific microsomal binding on apparent intrinsic clearance, and its prediction from physicochemical properties Drug Metab. Dispos. 2002, 30, 1497-1503
75. Austin, R. P.; Barton, P.; Mohmed, S.; Riley, R. J. The binding of drugs to hepatocytes and its relationship to physicochemical properties Drug Metab. Dispos. 2005, 33, 419-425
76. Hallifax, D.; Houston, J. B. Binding of drugs to hepatic microsomes: comment and assessment of current prediction methodology with recommendation for improvement Drug Metab. Dispos. 2006, 34, 1078
77. Smith, D. A.; Jones, B. C.; Walker, D. K. Design of Drugs Involving the Concepts and Theories of Drug Metabolism and Pharmacokinetics Med. Res. Rev. 1996, 16, 243-266
78. Brown, C. D. A.; Sayer, R.; Windass, A. S.; Haslam, I. S.; De Broe, M. E.; D'Haese, P. C.; Verhulst, A. Characterisation of human tubular cell monolayers as a model of proximal tubular xenobiotic handling Toxicol. Appl. Pharmacol. 2008, 233, 428-438
79. Paine, S. W.; Menochet, K.; Denton, R.; McGinnity, D. F.; Riley, R. J. Prediction of Human Renal Clearance from Preclinical Species for a Diverse Set of Drugs That Exhibit Both Active Secretion and Net Reabsorption Drug Metab. Dispos. 2011, 39, 1008-1013
80. Tahara, H.; Shono, M.; Kusuhara, H.; Kinoshita, H.; Fuse, E.; Takadate, A.; Otagiri, M.; Sugiyama, Y. Molecular cloning and functional analyses of OAT1 and OAT3 from cynomolgus monkey kidney Pharm. Res. 2005, 22, 647-660
81. Kato, Y.; Kuge, K.; Kusuhara, H.; Meier, P. J.; Sugiyama, Y. Gender difference in the urinary excretion of organic anions in rats J. Pharmacol. Exp. Ther. 2002, 302, 483-489
82. Nakakariya, M.; Shimada, T.; Irokawa, M.; Koibuchi, H.; Iwanaga, T.; Yabuuchi, H.; Maeda, T.; Tamai, I. Predominant Contribution of Rat Organic Anion Transporting Polypeptide-2 (Oatp2) to Hepatic Uptake of β-Lactam Antibiotics Pharm. Res. 2010, 25, 578-585
83. Kusuhara, H.; Sugiyama, Y. Pharmacokinetic modeling of the hepatobiliary transport mediated by cooperation of uptake and efflux transporters Drug Metab Rev. 2010, 42, 539-550
84. Shitara, Y.; Horie, T.; Sugiyama, Y. Transporters as a determinant of drug clearance and tissue distribution Eur. J. Pharm. Sci. 2006, 27, 425-446
85. Mahmood, I. Interspecies scaling of biliary excreted drugs: a comparison of several methods J. Pharm. Sci. 2005, 94, 883-892
86. Mahmood, I.; Sahajwalla, C. Interspecies scaling of biliary excreted drugs J. Pharm. Sci. 2002, 91, 1908-1014
87. Sawada, Y.; Hanano, M.; Sugiyama, Y.; Iga, T. Prediction of the disposition of β-lactam antibiotics in humans from pharmacokinetic parameters in animals J. Pharmacokinet. Biopharm. 1984, 12, 241-260
88. Scatina, J. A.; Hicks, D. R.; Kraml, M.; Cayen, M. N. Disposition of a new tetrahydrocarbazole analgesic drug in laboratory animals and man Xenobiotica 1989, 19, 991-1002
89. PaÌŠhlman, I.; Edholm, M.; Kankaanranta, S.; Odell, M.-L. Pharmacokinetics of Susalimod, a highly biliary excreted sulphasalazine analogue, in various species. Non precictable human clearance by allometric scaling Pharm. Pharmacol. Commum. 1998, 4, 493-498
90. Morris, M.; Yang, Y.; Gandhi, Y. A.; Bhansalia, S. G.; Benincosa, L. J. Interspecies scaling: prediction of human biliary clearance and comparison with QSPKR Biopharm. Drug Dispos. 2012, 33, 1-14
91. Grime, K. H.; Paine, S. W. Species Differences in Biliary Clearance and Possible Relevance of Hepatic Uptake and Efflux Transporters Involvement Drug Metab. Dispos. 2012, dmd.112.049312
92. Yamazaki, M.; Akiyama, S.; Nishigaki, R.; Sugiyama, Y. Uptake is the rate-limiting step in the overall hepatic elimination of pravastatin at steady-state in rats Pharm. Res. 1996, 13, 1559-1564
93. Gardiner, P.; Paine, S. W. The impact of hepatic uptake on the pharmacokinetics of organic anions Drug Metab. Dispos. 2011, 39, 1930-1938
94. Varma, M. V.; Chang, G.; Lai, Y.; Feng, B.; El-Kattan, A. F.; Litchfield, J.; Goosen, T. C. Physicochemical property space of hepatobiliary transport and computational models for predicting rat biliary excretion Drug Metab. Dispos. 2012, 40, 1527-1537
95. LeCluyse, E. L.; Audus, K. L.; Hochman, J. H. Formation of extensive canalicular networks by rat hepatocytes cultured in collagen-sandwich configuration Am. J. Physiol. 1994, 266 (6 Part 1) C1764-C1774
96. Caldwell, G. W.; Masucci, J. A.; Yan, Z.; Hageman, W. Allometric scaling of pharmacokinetic parameters in drug discovery: can human CL, Vss and t1/2 be predicted from in-vivo rat data? Allometric scaling of pharmacokinetic parameters in drug discovery: can human CL, Vss and t1/2 be predicted from in-vivo rat data? Eur. J. Drug Metab. Pharmacokinet. 2004, 29, 133-143
97. Tang, H.; Hussain, A.; Leal, M.; Mayersohn, M.; Fluhler, E. Interspecies Prediction of Human Drug Clearance Based on Scaling Data from One or Two Animal Species Drug Metab. Dispos. 2007, 35, 1886-1893
98. Wong, H.; Lewin-Koh, S. C.; Theil, F. P.; Hop, C. E. Influence of the compound selection process on the performance of human clearance prediction methods J. Pharm. Sci. 2012, 101, 509-515
99. Waring, M. J. Defining optimum lipophilicity and molecular weight ranges for drug candidates-Molecular weight dependent lower log D based on permeability Bioorg. Med. Chem. Lett. 2009, 19, 2844-2851
100. Comer, J. E. A. High throughput measurements of log D and pKa Methods Princ. Med. Chem. 2003, 18, 55-59
101. Martin, Y. A bioavailability score J. Med. Chem. 2005, 48, 3164-3170
102. Wenlock, M.; Tomkinson, N. T.; Leeson, P. Importance of physicochemical properties in drug discovery. Med. Chem. Drug Discovery 2012, in press.
103. Geerts, T.; Vander Hyden, Y. In silico predictions of ADME-Tox Predictions: Drug Absorption Comb. Chem. High Throughput Screening 2011, 14, 339-361
104. Takagi, T.; Ramachandran, C.; Bermejo, M.; Yamashita, S.; Yu, L. X.; Amidon, G. L. A Provisional biopharmaceutical classification of the top 200 oral drug products in the United States, Great Britain, Spain, and Japan Mol. Pharmaceutics 2006, 6, 631-643
105. Hansch, C.; Quinlan, J. E.; Lawrence, G. L. The linear free energy relationship between partition coefficients and the aqueous solubility of organic liquids J. Org. Chem. 1968, 33, 347-350
106. Segall, M. D. Multiparameter optimization: identifying high quality compounds with a balance of properties Curr. Pharm. Des. 2012, 18, 1292-1310
107. Jain, N.; Yalkowsky, S. H. Estimation of the aqueous solubility I: Application to organic nonelectrolytes J. Pharm. Sci. 2001, 90, 234-252
108. Abraham, M. H.; Le, J. The correlation and prediction of the solubility of molecules in water using an amended solvation energy relationship J. Pharm. Sci. 1999, 88, 868-880
109. Llinas, A.; Glen, R. C.; Goodman, J. M. Solubility challenge: can you predict solubilities of 32 molecules using a database of 100 measurements? J. Chem. Inf. Model. 2008, 48, 1289-1303
110. Hewitt, M.; Cronin, M. T. D.; Enoch, S. J.; Madden, J. C.; Roberts, D. W.; Dearden, C. In silico prediction of aqueous solubility: The solubility challenge J. Chem. Inf. Model. 2009, 49, 2572-2587
111. Bergström, C. A. S. Computational Models to Predict Aqueous Drug Solubility, Permeability and Intestinal Absorption Expert Opin. Drug Metab. Toxicol. 2005, 1, 613-627
112. Delaney, J. S. Predicting Aqueous Solubility From Structure Drug Discovery Today 2005, 10, 289-295
113. Dearden, J. C. In Silico Prediction of Aqueous Solubility Expert Opin. Drug Discovery 2006, 1, 31-52
114. Davis, A. M.; Bruneau, P. In Silico Prediction of Solubility. In Drug Bioavailabilty (40, Methods and Principles in Medicinal Chemistry), 2 nd ed.; van de Waterbeemd, H.; Testa, B., Eds; Wiley-VCH Verlag GmbH & Co. KGaA: Weinheim, Germany, 2009; pp 53-68.
115. Gleeson, M. P.; Hersey, A.; Hannongbua, S. In-Silico ADME Models: A General Assessment of their Utility in Drug Discovery Applications Curr. Top. Med. Chem. 2011, 11, 358-381
116. Rogers, S, L.; Davis, A. M.; Tomkinson, N. P.; van de Waterbeemd, H. QSAR modeling using automated updating correction libraries: application to a human plasma binding model J. Chem. Inf. Model. 2007, 47, 2401-2407
117. Rogers, S, L.; Davis, A. M.; Tomkinson, N. P.; van de Waterbeemd, H. Predictivity of simulated ADME AutoQSAR models over time Mol. Inf. 2011, 30, 256-266
118. Gleeson, M. P.; Waters, N. J.; Paine, S. W.; Davis, A. M. In silico human and rat vss quantitative structure-activity relationship models J. Med. Chem. 2006, 49, 1953-1963
119. Madden, J. C.; Cronin, T. D. Structure-based methods for the prediction of drug metabolism Expert Opin. Drug Metab. Toxicol. 2006, 2, 545-557
120. Yap, C. W.; Li, Z. R.; Chen, Y. Z. Quantitative structurepharmacokinetic relationships for drug clearance by using statistical learning methods J. Mol. Graphics Modell. 2006, 24, 383-395
121. Lee, P. H.; Cucurull-Sanchez, L.; Lu, J.; Du, Y. J. Development of in silico models for human liver microsomal stability J. Comput.-Aided. Mol. Des. 2007, 21, 665-673
122. Hu, Y.; Unwalla, R.; Denny, R. A.; Bikker, J.; Di, L.; Humblet, C. Development of QSAR models for microsomal stability: identification of good and bad structural features for rat, human and mouse microsomal stability J. Comput.-Aided Mol. Des. 2010, 24, 23-35
123. Yu, M. J. Predicting total clearance in humans from chemical structure J. Chem. Inf. Model 2010, 50, 1284-1295
124. Berellini, G.; Waters, N. J.; Lombardo, F. In silico prediction of total plasma clearance J. Chem. Inf. Model. 2012, 52, 2069-2078
125. Paine, S. W.; Barton, P.; Bird, J.; Denton, R.; Menochet, K.; Smith, A.; Tomkinson, N. P.; Chohan, K. K. A rapid computational filter for predicting the rate of human renal clearance J. Mol. Graphics Modell. 2010, 29, 529-537
126. Lou, L.; Johnson, J.; Hsueh, M.-H.; Zheng, J.; Cai, H.; Xin, B.; Chong, S.; He, K.; Harper, T. W. In silico prediction of biliary excretion of drugs in rat based on physicochemical properties Drug Metab. Dispos. 2010, 38, 422-430
127. rd ed.; Holford, N., Ed.; Adis International Limited: Auckland, New Zealand, 1998; pp 1-48.
128. th ed.; Gilman, A. G.; Goodman, L. S.; Rall, T. W.; Nies, A. S.; Taylor, P., Eds.; Macmillan Publishing Co.: New York, 1990; pp 1650-1735.